30th September 2020
On 11th September 2020, Professors Hemant Kocher and Nick Lemoine hosted the eighth London Pancreas Workshop (LPW) – a forum for state-of-the-art clinical and basic research in pancreatic cancer. In a first for the biennial event, this year’s LPW took place online with pre-recorded speaker presentations and live, interactive Q&A sessions.
Read more24th September 2020
A treatment combination involving the addition of a form of vitamin A to the current standard treatment regimen for pancreatic cancer is safe for patients, according to an early phase clinical trial led by Professor Hemant Kocher from Barts Cancer Institute, Queen Mary University of London.
Read more18th September 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.
Read more16th September 2020
Results from a phase I clinical trial led by Professor Peter Szlosarek were recently published in JTO Clinical and Research Reports. The trial was investigating the safety and efficacy of a new drug combination for the treatment of mesothelioma. We spoke to Professor Szlosarek to find out more about the trial, and how the drug combination may be able to help patients with mesothelioma.
Read more17th August 2020
For women at high risk of ovarian cancer, standard preventive practice is to offer removal of both the fallopian tubes and ovaries, but the surgery induces menopause in women who have not yet reached this stage of life. A proposed alternative two step surgical protocol, which delays the induced menopause caused by the removal of the ovaries, is highly acceptable to this premenopausal group of women.
Read more29th May 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.
Read more